Actinium Pharmaceuticals Inc (ATNM) Sees Significant Drop in Short Interest

Actinium Pharmaceuticals Inc (NYSE:ATNM) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 1,469,849 shares, a drop of 8.5% from the August 31st total of 1,606,358 shares. Based on an average daily trading volume, of 193,919 shares, the days-to-cover ratio is presently 7.6 days. Currently, 3.4% of the shares of the stock are short sold.

Actinium Pharmaceuticals (NYSE:ATNM) opened at 1.35 on Friday. The firm has a 50-day moving average of $1.70 and a 200 day moving average of $1.81. The company’s market capitalization is $64.42 million. Actinium Pharmaceuticals has a 12-month low of $1.29 and a 12-month high of $3.50.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

5 Day Chart for NYSE:ATNM

Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.